Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Today's News: Middle East.
Press releases published on June 24, 2025
Quoin Pharmaceuticals Announces FDA Grants Rare Pediatric Disease Designation for QRX003 in Netherton Syndrome
GlobeNewswire
·
June 24, 2025
ASHBURN, Va., June 24, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (“Quoin” or the “Company”), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced that the U.S. Food and Drug …
Veru Reports Positive Results from Phase 2b QUALITY and Maintenance Extension Study Showing Enobosarm Significantly Reduced Body Weight Regain, Prevented Fat Regain, and Preserved Lean Mass After Semaglutide Discontinuation
GlobeNewswire
·
June 24, 2025
--During the Maintenance Period of 12 weeks after discontinuing semaglutide (GLP-1 receptor agonist), placebo group regained 43% of body weight that was previously lost during Phase 2b QUALITY study; on average, enobosarm 3mg significantly reduced body …
SafeGuest Launches Game-Changing Risk Scoring Tool to Help Airbnb and Short-Let Hosts Stop Problem Guests — For Free
GlobeNewswire
·
June 24, 2025
LONDON, June 24, 2025 (GLOBE NEWSWIRE) -- SafeGuest, the safety-first platform for short-term rental hosts and property managers, today announced the launch of its revolutionary Guest Risk Assessment Tool — a free service that helps hosts instantly …
Clearmind Medicine Joins Forces with Leading US Political Firm to Promote Psychedelic Therapeutics
GlobeNewswire
·
June 24, 2025
Vancouver, Canada, June 24, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to …
SELLAS Life Sciences to be Added to Russell 3000® and Russell 2000® Indexes
GlobeNewswire
·
June 24, 2025
NEW YORK, June 24, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, …
Aardvark Therapeutics to Join Prader-Willi Syndrome Community at the 2025 United in Hope Conference
GlobeNewswire
·
June 24, 2025
SAN DIEGO, June 24, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the …
MindRank Announces Positive Phase 2b Results for AI-Designed Oral GLP-1 Receptor Agonist MDR-001 in Adults with Obesity or Overweight
GlobeNewswire
·
June 24, 2025
MDR-001 achieved statistically significant weight reductions of 8.2% to 10.3% at 24 weeks compared to 2.5% with placebo (p<0.00001), with up to 48.1% of participants achieving ≥10% weight loss. No treatment-related serious adverse events were reported. …
Lexeo Therapeutics, Perceptive Xontogeny Venture Funds and venBio Partners Announce Partnership to Advance Novel Cardiac RNA Therapeutics
GlobeNewswire
·
June 24, 2025
Up to $40 Million Private Equity Financing into a New Entity Addressing Cardiac Genetic Diseases that Existing AAV Platforms are Unable to Treat Lexeo Contributing Expertise and Know-How in Cardiac Genetic Medicines, Preclinical Intellectual Property, and …
Abschließende Daten aus der realen PEARL-Studie von Teva untermauern die langfristige Wirksamkeit von AJOVY® (fremanezumab) für die Prävention chronischer und episodischer Migräne
GlobeNewswire
·
June 24, 2025
Die abschließende Analyse der realen PEARL-Studie für die Migräneprävention wurde auf dem 11. Kongress der European Academy of Neurology (EAN 2025) in Helsinki präsentiert1,2 Fremanezumab demonstrierte eine langfristige Wirksamkeit und ein günstiges …
Les données définitives de l’étude PEARL menée par Teva en conditions réelles confirment l’efficacité à long terme d’AJOVY® (frémanézumab) pour la prévention de la migraine chronique et épisodique
GlobeNewswire
·
June 24, 2025
L’analyse finale de l’étude PEARL ciblée sur la prévention de la migraine en conditions réelles a été présentée au 11ᵉ congrès de l’Académie européenne de neurologie (le congrès EAN 2025) qui s’est tenu à Helsinki1,2 Le frémanézumab a montré une efficacité …
RECORDATI ANNOUNCES EXCLUSIVE LICENSING & SUPPLY AGREEMENT WITH AMARIN TO COMMERCIALIZE VAZKEPA® IN EUROPE
GlobeNewswire
·
June 24, 2025
RECORDATI ANNOUNCES EXCLUSIVE LICENSING …
Fortrea & Emery Pharma Announce Strategic Collaboration to Deliver FDA Compliant Drug-Drug-Interaction Studies Using Rifampin
GlobeNewswire
·
June 24, 2025
DURHAM, N.C., June 24, 2025 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (CRO), today announced a strategic collaboration with Emery Pharma, a leading analytical and bioanalytical CRO providing …
Revolution Medicines Enters Into $2 Billion Flexible Funding Agreement with Royalty Pharma to Support Global Development and Commercialization of RAS(ON) Inhibitor Portfolio for Patients with RAS-Addicted Cancers
GlobeNewswire
·
June 24, 2025
Flexible funding provides $2 billion in committed capital comprised of up to $1.25 billion of synthetic royalty and up to $750 million in corporate debt Company moving forward with independent global commercialization strategy to prioritize patient reach …
Erdene Releases 2025 Shareholder Letter
GlobeNewswire
·
June 24, 2025
HALIFAX, Nova Scotia, June 24, 2025 (GLOBE NEWSWIRE) -- Erdene Resource Development Corporation (TSX:ERD | MSE:ERDN) (“Erdene” or the “Company”) is pleased to publish its 2025 Letter to Shareholders authored by President and CEO, Peter Akerley. To read the …
Bitcoin Solaris Gains Momentum with Confirmed LBank Exchange Listing
GlobeNewswire
·
June 24, 2025
TALLINN, Estonia, June 24, 2025 (GLOBE NEWSWIRE) -- Bitcoin Solaris (BTC-S) has officially confirmed its upcoming listing on LBank, a leading centralized exchange known for accelerating the visibility and accessibility of promising digital assets. This …
The Michelin Guide Expands Its Culinary Horizons to Saudi Arabia
GlobeNewswire
·
June 24, 2025
The MICHELIN Guide announced its arrival in a new destination: Saudi Arabia, for an upcoming 2026 edition. The restaurant selection for the inaugural edition will be unveiled towards the end of the year 2025. The renowned anonymous MICHELIN Inspectors are …
AAS Miner will become the top free cloud mining platform for passive income from mining BTC, ETH and other cryptocurrencies in 2025
GlobeNewswire
·
June 24, 2025
Hale, Altrincham, United Kingdom, June 24, 2025 (GLOBE NEWSWIRE) -- With the booming digital currency market, mining has become a new outlet for wealth pursued by many investors. However, traditional mining is daunting due to problems such as expensive …
Pharming Group to host webcast on findings of a new study published in Cell advancing functional classification of variants of uncertain significance (VUS) to improve APDS diagnosis
GlobeNewswire
·
June 24, 2025
For media and investors only Researchers identified variants which may cause activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) Results enable clinical genetic testing labs to appropriately reclassify VUSs, accelerating the path to a …